- Trials with a EudraCT protocol (135)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
135 result(s) found for: White Matter.
Displaying page 1 of 7.
EudraCT Number: 2017-001438-25 | Sponsor Protocol Number: VWM1 | Start Date*: 2020-04-21 |
Sponsor Name:VU University Medical Center | ||
Full Title: A Study to Explore the Safety, Tolerability, Pharmacokinetic Profile, and Potential Efficacy of Guanabenz in Patients With Early Childhood Onset Vanishing White Matter (VWM) | ||
Medical condition: Vanishing white matter | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003622-16 | Sponsor Protocol Number: T214/2016 | Start Date*: 2017-09-19 |
Sponsor Name:Turku University Hospital | ||
Full Title: Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study. | ||
Medical condition: Multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001235-20 | Sponsor Protocol Number: 14.0189 | Start Date*: 2015-06-05 |
Sponsor Name:St George's University of London | ||
Full Title: Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease | ||
Medical condition: PARTICIPANTS WITH EVIDENCE OF CEREBRAL SMALL VESSEL DISEASE | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023996-25 | Sponsor Protocol Number: 26081985 | Start Date*: 2010-12-21 |
Sponsor Name: | ||
Full Title: The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis. | ||
Medical condition: Multiple sclerosis (both relapsing remitting and progressive forms) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004158-40 | Sponsor Protocol Number: P170702J | Start Date*: 2018-09-11 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 | |||||||||||||
Medical condition: Patients with Relapsing MS or primary progressive MS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001542-17 | Sponsor Protocol Number: T109/2019Xe-SAH | Start Date*: 2020-09-17 | |||||||||||
Sponsor Name:Timo Laitio | |||||||||||||
Full Title: Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage | |||||||||||||
Medical condition: Acute rupture of cerebral aneurysm, subarachnoid hemorrhage (SAH), unconsciousness, brain injury. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016703-35 | Sponsor Protocol Number: NAPMSv3.2 | Start Date*: 2010-01-08 | ||||||||||||||||
Sponsor Name:Dansk Multipel Sclerose Center | ||||||||||||||||||
Full Title: Natalizumabbehandling af progressiv multipel sklerose | ||||||||||||||||||
Medical condition: Secondary progressive multiple sclerosis and primary progressive multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002636-82 | Sponsor Protocol Number: OTL-200-07 | Start Date*: 2019-12-02 | |||||||||||
Sponsor Name:Orchard Therapeutics (Europe) Limited | |||||||||||||
Full Title: An open label, non-randomised trial to evaluate the safety and efficacy of a single infusion of OTL-200 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD) | |||||||||||||
Medical condition: Metachromatic Leukodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001589-16 | Sponsor Protocol Number: 344-13-03-02-2010 | Start Date*: 2011-06-13 |
Sponsor Name:HUCH Eye Hospital | ||
Full Title: MINOPTIC - A prospective, double-masked, placebo-controlled study on efficacy and safety of minicycline in the treatment of optic neuritis | ||
Medical condition: optic neuritis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003209-14 | Sponsor Protocol Number: 5815 | Start Date*: 2014-09-01 |
Sponsor Name:Hôpitaux Universitaires de Strasbourg | ||
Full Title: ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS | ||
Medical condition: MULTIPLE SCLEROSIS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001735-49 | Sponsor Protocol Number: CTU/2015/174 | Start Date*: 2019-07-01 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial | |||||||||||||
Medical condition: Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003575-21 | Sponsor Protocol Number: | Start Date*: 2017-07-25 | |||||||||||
Sponsor Name:MRC Clinical Trials Unit at UCL | |||||||||||||
Full Title: A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy. | |||||||||||||
Medical condition: Hepatic steatosis in adults with chronic HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005435-87 | Sponsor Protocol Number: FIBHGM-ECNC002-2012 | Start Date*: 2013-02-14 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica Hospital Gregorio Marañón | |||||||||||||
Full Title: EFFECT OF ADJUVANT TREATMENT WITH N - ACETYLCYSTEINE DURING 48 WEEKS ON THE LOSS OF GREY SUBSTANCE AND OXIDATIVE METABOLISM IN PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES: BLIND, PLACEBO-CONTROLLE... | |||||||||||||
Medical condition: PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007394-22 | Sponsor Protocol Number: PK11195 | Start Date*: 2008-05-22 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (... | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001161-14 | Sponsor Protocol Number: CAMMS 323 | Start Date*: 2007-08-24 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) SE (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003127-38 | Sponsor Protocol Number: NL71001.029.19 | Start Date*: 2020-04-09 |
Sponsor Name:VUmc Neurology Department | ||
Full Title: Efficacy of add-on high dose simvastatin on markers for disease progression in MS patients treated with ocrelizumab and natalizumab (SIMSON), a phase II clinical trial. | ||
Medical condition: Multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003099-39 | Sponsor Protocol Number: LWH0604 | Start Date*: 2008-08-21 |
Sponsor Name:Liverpool Women's NHS Foundation Trust Hospital | ||
Full Title: A Randomised Controlled Trial of Thyroxine in Preterm Infants Under 28 weeks' Gestation. | ||
Medical condition: Hypothyroidism is a condition where there is a lack of thyroid hormone in the body. Thyroid hormones are important for normal brain development and growth. Children who are born with low thyroid ho... | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002329-27 | Sponsor Protocol Number: ETLAS-2 | Start Date*: 2020-12-10 | ||||||||||||||||
Sponsor Name:Herlev Gentofte Hospital | ||||||||||||||||||
Full Title: Improving cerebral blood flow and cognition in patient with cerebral small vessel disease. The ETLAS-2 Trial. | ||||||||||||||||||
Medical condition: Cerebral small vessel disease and stroke. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004132-22 | Sponsor Protocol Number: NPH-01 | Start Date*: 2021-01-20 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: Double-blind randomized acetazolamide trial in normal pressure hydrocephalus | |||||||||||||
Medical condition: Normal pressure hydrocephalus | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004785-18 | Sponsor Protocol Number: PKBoxing-1 | Start Date*: 2014-11-18 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: PET imaging of neuroinflammatory consequences of chronic repetitive head injury in Muay Thai boxing | ||
Medical condition: n/a | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.